Evidence map›Paper›PMID 37273907›Full record

ArticleFrontiers in molecular neuroscience2023

Implications of specific lysine residues within ataxin-3 for the molecular pathogenesis of Machado-Joseph disease.

Priscila Pereira Sena, Jonasz Jeremiasz Weber, Sercan Bayezit, Rafael Saup, Rana Dilara Incebacak Eltemur, Xiaoling Li, Ana Velic, Jaqueline Jung, Boris Macek, Huu Phuc Nguyen and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in molecular neuroscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Priscila Pereira SenaInstitute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.
Jonasz Jeremiasz WeberInstitute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.
Sercan BayezitInstitute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.
Rafael SaupInstitute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.
Rana Dilara Incebacak EltemurInstitute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.
Xiaoling LiInstitute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.
Ana VelicProteome Center Tübingen, University of Tübingen, Tübingen, Germany.
Jaqueline JungInstitute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.
Boris MacekProteome Center Tübingen, University of Tübingen, Tübingen, Germany.
Huu Phuc NguyenDepartment of Human Genetics, Ruhr University Bochum, Bochum, Germany.
Olaf RiessInstitute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.
Thorsten SchmidtInstitute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.
University of Tübingen · DERuhr University Bochum · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lysine residues are one of the main sites for posttranslational modifications of proteins, and lysine ubiquitination of the Machado-Joseph disease protein ataxin-3 is implicated in its cellular function and polyglutamine expansion-dependent toxicity. Despite previously undertaken efforts, the individual roles of specific lysine residues of the ataxin-3 sequence are not entirely understood and demand further analysis. By retaining single lysine residues of otherwise lysine-free wild-type and polyglutamine-expanded ataxin-3, we assessed the effects of a site-limited modifiability on ataxin-3 protein levels, aggregation propensity, localization, and stability. We confirmed earlier findings that levels of lysine-free ataxin-3 are reduced due to its decreased stability, which led to a diminished load of SDS-insoluble species of its polyglutamine-expanded form. The isolated presence of several single lysine residues within the N-terminus of polyglutamine-expanded ataxin-3 significantly restored its aggregate levels, with highest fold changes induced by the presence of lysine 8 or lysine 85, respectively. Ataxin-3 lacking all lysine residues presented a slightly increased nuclear localization, which was counteracted by the reintroduction of lysine 85, whereas presence of either lysine 8 or lysine 85 led to a significantly higher ataxin-3 stability. Moreover, lysine-free ataxin-3 showed increased toxicity and binding to K48-linked polyubiquitin chains, whereas the reintroduction of lysine 85, located between the ubiquitin-binding sites 1 and 2 of ataxin-3, normalized its binding affinity. Overall, our data highlight the relevance of lysine residues 8 and 85 of ataxin-3 and encourage further analyses, to evaluate the potential of modulating posttranslational modifications of these sites for influencing pathophysiological characteristics of the Machado-Joseph disease protein.

Indexed as

ataxin-3deubiquitinasePolyglutamine diseasesposttranslational modificationproteasomal degradationprotein aggregationspinocerebellar ataxia type 3ubiquitination

Identifiers

PMID37273907
PMCPMC10235640
OpenAlexW4377139153

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.